Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 2:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 1,765 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced/Metastatic Solid Malignancies
Interventions
IBI308
Drug
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
7
States / cities
Orange, California • Atlanta, Georgia • Detroit, Michigan + 4 more
Conditions
Male Breast Cancer, Recurrent Melanoma, Stage IV Breast Cancer, Stage IV Melanoma, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific, Hepatocellular Carcinoma
Interventions
propranolol hydrochloride, Correlative Studies
Drug · Other
Lead sponsor
William Carson
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Advanced Solid Tumors, Advanced B-cell NHL
Interventions
Urelumab, Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
11
States / cities
Palo Alto, California • Tampa, Florida • Chicago, Illinois + 6 more
Conditions
Metastasis
Interventions
THOR-707, Checkpoint inhibitor, anti-EGFR antibody
Drug
Lead sponsor
Synthorx, Inc, a Sanofi company
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Scottsdale, Arizona • Denver, Colorado • Sarasota, Florida + 4 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
vorinostat, gemcitabine hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Houston, Texas
Conditions
Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
Interventions
INCA33890, bevacizumab, FOLFIRI, FOLFOX, Cetuximab, ADG126
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
11
States / cities
Los Angeles, California • Boston, Massachusetts • Grand Rapids, Michigan + 7 more
Conditions
Advanced and/or Metastatic Solid Tumors Known to Express B7-H3
Interventions
MX006
Drug
Lead sponsor
Myricx Pharma Limited
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Sarasota, Florida • Atlanta, Georgia • Baltimore, Maryland + 3 more
Conditions
Advanced Malignant Solid Neoplasm, HIV Infection, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Unresectable Solid Neoplasm
Interventions
Cabozantinib S-malate, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
20
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 9 more
Conditions
Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer (PROC), Serous Epithelial Ovarian Cancer, Fallopian Tube Cancer
Interventions
DSP-7888 Dosing Emulsion, Nivolumab, Pembrolizumab
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 14 more
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Non Small Cell Lung Cancer
Interventions
KK2269, Docetaxel
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
7
States / cities
Scottsdale, Arizona • Duarte, California • Newport Beach, California + 4 more
Conditions
Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Kidney Medullary Carcinoma, Metastatic Malignant Germ Cell Tumor, Metastatic Malignant Solid Neoplasm, Metastatic Paraganglioma, Metastatic Penile Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Small Cell Carcinoma, Stage III Adrenal Cortex Carcinoma AJCC v7, Stage IV Adrenal Cortex Carcinoma AJCC v7, Stage IV Penile Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Unresectable Adrenal Gland Pheochromocytoma, Unresectable Paraganglioma, Unresectable Skin Squamous Cell Carcinoma, Unresectable Solid Neoplasm, Vascular Neoplasm
Interventions
Laboratory Biomarker Analysis, Pembrolizumab, Questionnaire Administration
Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 1Phase 2 Interventional Results available

Sym004 in Patients With Advanced Solid Tumors

NCT01117428
Conditions
Metastatic Colorectal Cancer
Interventions
Sym004
Drug
Lead sponsor
Symphogen A/S
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Metastatic Cancers
Interventions
Gene Modified T Cells
Genetic
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
American ginseng, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
326
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 208 more
Conditions
Advanced or Metastatic Solid Tumors
Interventions
MRG004A
Drug
Lead sponsor
Lepu Biopharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Orange, California • New York, New York • Canton, Ohio + 3 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
epirubicin hydrochloride, panobinostat, gene expression analysis, protein expression analysis, western blotting, immunologic technique, laboratory biomarker analysis, pharmacological study
Drug · Genetic · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
San Francisco, California
Conditions
Urethral Neoplasms, Neoplasms, Urethral, Cancer of the Urethra, Urethral Cancer
Interventions
Gemcitabine, Carboplatin, Lenalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Terminated Phase 1Phase 2 Interventional Results available

MGC018 With or Without MGA012 in Advanced Solid Tumors

NCT03729596
Conditions
Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult, Metastatic Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer
Interventions
vobramitamab duocarmazine
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
9
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Baltimore, Maryland + 5 more
Conditions
Metastatic Solid Neoplasm, Lymphoma
Interventions
SYNB1891, Atezolizumab
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Aurora, Colorado • Hackensack, New Jersey • Columbus, Ohio + 3 more
Conditions
Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage III Pancreatic Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Gallbladder Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Pancreatic Cancer, Unresectable Gallbladder Carcinoma, Unresectable Pancreatic Cancer
Interventions
Cisplatin, Docetaxel, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Pharmacological Study, Recombinant EphB4-HSA Fusion Protein
Drug · Other · Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Newport Beach, California
Active, not recruiting Phase 2 Interventional Results available

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

NCT03994796
Conditions
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
Interventions
Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
435
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 306 more
Conditions
Brain and Central Nervous System Tumors, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
temozolomide, thalidomide, radiation therapy
Drug · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
5
States / cities
Decatur, Illinois • Goldsboro, North Carolina • Winston-Salem, North Carolina + 2 more
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation
Interventions
PRT3789, Docetaxel
Drug
Lead sponsor
Prelude Therapeutics Incorporated
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
20
States / cities
Sacramento, California • Santa Monica, California • New Haven, Connecticut + 13 more
Conditions
Solid Tumors
Interventions
Runimotamab, Trastuzumab, Tocilizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
5
States / cities
New Haven, Connecticut • Saint Louis, Michigan • New York, New York + 2 more